Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.

Autor: Zhou F; Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China., Guo L; Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Jazyk: angličtina
Zdroj: Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 596-602.
DOI: 10.1080/16078454.2022.2072062
Abstrakt: Objective: Long non-coding RNA ANGPTL1-3 (lnc-ANGPTL1-3) is previously observed to induce bortezomib resistance via targeting microRNA-30a (miR-30a) in multiple myeloma (MM). Hence, this study aimed to further explore the relationship between lnc-ANGPTL1-3 and miR-30a and their linkage with disease properties and prognosis in bortezomib-treated MM patients.
Methods: Fifty-nine MM patients underwent treatment with the bortezomib-based regimen, and 30 healthy donors were consecutively enrolled. Bone marrow samples were collected from MM patients (before therapy) and healthy donors; then, plasma cells were separated for lnc-ANGPTL1-3 and miR-30a detection by RT-qPCR. Then treatment response, progression-free survival (PFS), and overall survival (OS) of MM patients were assessed.
Results: Lnc-ANGPTL1-3 was upregulated while miR-30a was downregulated in MM patients compared to healthy donors (both P  < 0.001), then a negative correlation between lnc-ANGPTL1-3 and miR-30a was found in MM patients ( P  < 0.001) instead of in health donors ( P  = 0.188). In MM patients, lnc-ANGPTL1-3 correlated with increased t (4;14) ( P  = 0.033), Del (17p) ( P  = 0.018), ISS stage ( P  = 0.020), R-ISS stage ( P  = 0.025) but not t (14;16) ( P  = 0.255) or Durie-Salmon stage ( P  = 0.186); while miR-30a only related to decreased t (14;16) ( P  = 0.025) and R-ISS stage ( P  = 0.006). Besides, lnc-ANGPTL1-3 predicted lower complete response (CR) ( P  = 0.034), poor PFS ( P  = 0.016) and OS ( P  = 0.041) but not objective response rate (ORR) ( P  = 0.128). However, miR-30a forecasted higher CR ( P  = 0.013), prolonged PFS ( P  = 0.014), and OS ( P  = 0.045) but not ORR ( P  = 0.407).
Conclusion: Lnc-ANGPTL1-3 negative correlates with miR-30a, which links with key cytogenetic features, ISS/R-ISS stage, and prognosis in MM patients who underwent treatment of bortezomib-based regimen.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje